Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab

Abstract Although several prognostic factors in nivolumab therapy have been reported in recurrent or metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological f...

Full description

Bibliographic Details
Main Authors: Kiyoshi Minohara, Takuma Matoba, Daisuke Kawakita, Gaku Takano, Keisuke Oguri, Akihiro Murashima, Kazuhiro Nakai, Sho Iwaki, Wataru Hojo, Ayano Matsumura, Shinya Ozaki, Taijiro Ozawa, Ikuma Harata, Nobukazu Tanaka, Shinichiro Maseki, Hiroshi Tsuge, Sae Imaizumi, Shoji Mitsuya, Kazuho Moribe, Shinichi Esaki, Shinichi Iwasaki
Format: Article
Language:English
Published: Nature Portfolio 2021-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-96538-7

Internet

https://doi.org/10.1038/s41598-021-96538-7

Similar Items